Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 22;13(18):5627.
doi: 10.3390/jcm13185627.

Impact of GLP-1 Receptor Agonists in Gastrointestinal Endoscopy: An Updated Review

Sahib Singh  1 , Saurabh Chandan  2 , Dushyant Singh Dahiya  3 , Ganesh Aswath  4 , Daryl Ramai  5 , Marcello Maida  6 , Andrea Anderloni  7 , Nicola Muscatiello  8 , Antonio Facciorusso  8   9
Affiliations
Review

Impact of GLP-1 Receptor Agonists in Gastrointestinal Endoscopy: An Updated Review

Sahib Singh et al. J Clin Med. .

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become one of the most popular medications for patients with diabetes and obesity. Due to their effects on gut motility via central or parasympathetic pathways, there have been concerns about an increased incidence of retained gastric contents and risk of aspiration in the perioperative period. Hence, the American Society of Anesthesiologists (ASA) recommends holding GLP-1 RAs on the procedure day or a week before the elective procedure based on the respective daily or weekly formulations, regardless of the dose, indication (obesity or diabetes), or procedure type. On the contrary, the American Gastroenterological Association (AGA) advises an individualized approach, stating that more data are needed to decide if and when the GLP-1 RAs should be held prior to elective endoscopy. Several retrospective and prospective studies, along with meta-analyses, have been published since then evaluating the role of GLP-1 RAs in patients scheduled for endoscopic procedures. In this review, we discuss the current clinical guidelines and available studies regarding the effect of GLP-1 RAs on GI endoscopies.

Keywords: capsule endoscopy; colonoscopy; glucagon-like peptide-1 receptor agonists; upper endoscopy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Impact of GLP-1 RAs on endoscopy.
See this image and copyright information in PMC

References

    1. Drucker D.J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27:740–756. doi: 10.1016/j.cmet.2018.03.001. - DOI - PubMed
    1. Qaseem A., Obley A.J., Shamliyan T., Hicks L.A., Harrod C.S., Crandall C.J., Clinical Guidelines Committee of the American College of Physicians. Balk E.M., Cooney T.G., Cross J.T., Jr., et al. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann. Intern. Med. 2024;177:658–666. doi: 10.7326/M23-2788. - DOI - PMC - PubMed
    1. Grunvald E., Shah R., Hernaez R., Chandar A.K., Pickett-Blakely O., Teigen L.M., Harindhanavudhi T., Sultan S., Singh S., Davitkov P., et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022;163:1198–1225. doi: 10.1053/j.gastro.2022.08.045. - DOI - PubMed
    1. Watanabe J.H., Kwon J., Nan B., Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J. Am. Pharm. Assoc. (2003) 2024;64:133–138. doi: 10.1016/j.japh.2023.10.002. - DOI - PubMed
    1. Arvanitakis K., Koufakis T., Popovic D., Maltese G., Mustafa O., Doumas M., Giouleme O., Kotsa K., Germanidis G. GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: From Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use. Curr. Obes. Rep. 2023;12:61–74. doi: 10.1007/s13679-023-00506-3. - DOI - PubMed

LinkOut - more resources